The question bank is the fastest way to start, but PMHNP Helper also includes board-review planning, student resources, and plain-English guidance for psychiatric nurse practitioner students who are still learning the exam landscape.
A 79-year-old man with a history of major depressive disorder, type 2 diabetes, osteoarthritis, and a recent hip fracture repaired six weeks ago is being seen for follow-up after starting sertraline 25 mg daily four weeks ago. His depressive symptoms have shown minimal improvement, and he continues to report persistent sadness, loss of interest, fatigue, and poor sleep. He takes metformin, lisinopril, amlodipine, and was recently started on naproxen by his orthopedist for persistent hip pain. His sodium level was 142 mEq/L at baseline. He denies suicidal ideation. The PMHNP is considering the next step in medication management.
Explanation
In geriatric depression management, optimizing the dose of the initial antidepressant before switching or augmenting is a fundamental principle. Sertraline 25 mg is a starting dose in older adults, and an increase to 50 mg is the appropriate next step. In this patient, the concurrent use of naproxen with an SSRI creates two important safety concerns: an increased risk of SSRI-induced hyponatremia (SIADH), which is potentiated by NSAIDs, and an increased risk of gastrointestinal bleeding due to the antiplatelet effects of SSRIs combined with the mucosal effects of NSAIDs. Serum sodium monitoring and interdisciplinary coordination regarding pain management are essential components of safe geriatric psychopharmacology.
Key Takeaway
When managing geriatric depression, optimize the antidepressant dose before switching or augmenting, and monitor for drug interactions including the increased risks of hyponatremia and GI bleeding with concurrent SSRI and NSAID use.